PROSPECT-AD

Speech impairments are a feature of the early stages of Alzheimer's disease and, consequently, the analysis of speech performance is a promising new digital biomarker for the detection of the disease. The aim of PROSPECT-AD is to validate speech biomarkers for the identification of individuals with early signs of Alzheimer's and monitor them longitudinally. In addition, digital biomarkers of language and speech open the door to screening methods for populations at greater risk of suffering from the disease at very early stages, necessary for future clinical trials on Alzheimer's disease-modifying drugs. PROSPECT-AD collects data from 1,000 participants from European cohorts, 100 of them from the BBRC Beta-AARC study.